Solstice Pharmaceuticals develops cartridge systems for intravenous ultrasound contrast agents, utilizing uniform lipid-coated gas-filled microbubbles to enhance imaging quality. Their technology addresses the need for improved diagnostic accuracy in ultrasound examinations, allowing healthcare providers to spend more time with patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current ultrasound contrast agents often lack uniformity in microbubble size, leading to inconsistent image enhancement and potentially compromising diagnostic accuracy. Traditional activation methods for these agents can also be time-consuming and may not guarantee optimal microbubble characteristics.
Solution
Solstice Pharmaceuticals develops and manufactures Harmono-T®, an intravenous ultrasound contrast agent that utilizes uniform, lipid-coated, gas-filled microbubbles to enhance ultrasound image quality. The company's Harmono-T® product is designed to improve diagnostic value in ultrasound examinations. To ensure consistent activation, Solstice Pharmaceuticals also provides the Activation Station, an automated device that prepares the Harmono-T® contrast agent at the patient's bedside, guaranteeing size uniformity and optimal contrast enhancement during ultrasound procedures. This system allows healthcare providers to spend more time with patients while ensuring high-quality imaging.
Target Audience
The primary target audience includes healthcare professionals, such as radiologists and sonographers, who perform diagnostic and therapeutic ultrasound procedures in hospitals, imaging centers, and clinics.
Features
- Harmono-T® intravenous ultrasound contrast agent with uniform lipid-coated gas-filled microbubbles
- Activation Station for automated, point-of-care activation of Harmono-T®
- Activation Station guarantees size uniformity of microbubbles for improved contrast enhancement
- Easy-to-use cartridge system for Harmono-T®